Načítá se...

NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bakulin, Igor, Pasechnikov, Victor, Varlamicheva, Anna, Sannikova, Irina
Médium: Artigo
Jazyk:Inglês
Vydáno: Baishideng Publishing Group Inc 2014
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4033290/
https://ncbi.nlm.nih.gov/pubmed/24868326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v6.i5.326
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!